Veru is a biotechnology business based in the US. Veru shares (VERU) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.87 – a decrease of 4.69% over the previous week. Veru employs 189 staff and has a trailing 12-month revenue of around $14.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.87 |
|---|---|
| 52-week range | $0.36 - $1.92 |
| 50-day moving average | $0.82 |
| 200-day moving average | $0.85 |
| Wall St. target price | $3.40 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.30 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.8445 from 2024-10-18
| 1 week (2024-10-15) | -7.64% |
|---|---|
| 1 month (2024-09-20) | 8.30% |
| 3 months (2024-07-22) | -12.02% |
| 6 months (2024-04-22) | -33.50% |
| 1 year (2023-10-20) | 4.26% |
|---|---|
| 2 years (2022-10-21) | -92.45% |
| 3 years (2021-10-22) | 8.09 |
| 5 years (2019-10-22) | 1.97 |
| Revenue TTM | $14.1 million |
|---|---|
| Gross profit TTM | $30.6 million |
| Return on assets TTM | -64.36% |
| Return on equity TTM | -126.72% |
| Profit margin | -265.42% |
| Book value | $0.26 |
| Market Capitalization | $136.5 million |
TTM: trailing 12 months
We're not expecting Veru to pay a dividend over the next 12 months.
Over the last 12 months, Veru's shares have ranged in value from as little as $0.36 up to $1.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veru's is -0.479. This would suggest that Veru's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Veru has bucked the trend.
Veru Inc. , a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.